Innoviva, Inc. (INVA)
INVA Stock Price Chart
Explore Innoviva, Inc. interactive price chart. Choose custom timeframes to analyze INVA price movements and trends.
INVA Company Profile
Discover essential business fundamentals and corporate details for Innoviva, Inc. (INVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Oct 2004
Employees
127.00
Website
https://www.inva.comCEO
Pavel Raifeld
Description
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
INVA Financial Timeline
Browse a chronological timeline of Innoviva, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.44, while revenue estimate is $110.98m.
Earnings released on 6 May 2026
EPS came in at $0.44 surpassing the estimated $0.43 by +2.33%, while revenue for the quarter reached $97.99m , missing expectations by -3.52%.
Earnings released on 25 Feb 2026
EPS came in at $1.94 surpassing the estimated $0.34 by +470.59%, while revenue for the quarter reached $114.61m , beating expectations by +11.68%.
Earnings released on 5 Nov 2025
EPS came in at $1.08 surpassing the estimated $0.46 by +134.78%, while revenue for the quarter reached $107.80m , beating expectations by +6.18%.
Earnings released on 6 Aug 2025
EPS came in at $0.77 surpassing the estimated $0.57 by +35.09%, while revenue for the quarter reached $100.28m , beating expectations by +10.34%.
Earnings released on 7 May 2025
EPS came in at $0.25 falling short of the estimated $0.29 by -13.79%, while revenue for the quarter reached $88.63m , beating expectations by +7.21%.
Earnings released on 26 Feb 2025
EPS came in at $0.57 surpassing the estimated $0.34 by +67.65%, while revenue for the quarter reached $91.81m , missing expectations by -0.85%.
Earnings released on 6 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.27 by -92.59%, while revenue for the quarter reached $89.51m , beating expectations by +1.54%.
Earnings released on 31 Jul 2024
EPS came in at $0.68 surpassing the estimated $0.24 by +183.33%, while revenue for the quarter reached $103.35m , beating expectations by +38.38%.
Earnings released on 8 May 2024
EPS came in at $0.46 surpassing the estimated $0.17 by +170.59%, while revenue for the quarter reached $80.96m , beating expectations by +19.05%.
Earnings released on 29 Feb 2024
EPS came in at $0.76 surpassing the estimated $0.23 by +230.43%, while revenue for the quarter reached $89.27m , beating expectations by +18.23%.
Earnings released on 1 Nov 2023
EPS came in at $0.98 surpassing the estimated $0.27 by +262.96%, while revenue for the quarter reached $67.26m , missing expectations by -10.93%.
Earnings released on 2 Aug 2023
EPS came in at $0.08 falling short of the estimated $0.26 by -69.23%, while revenue for the quarter reached $80.99m , beating expectations by +17.52%.
Earnings released on 9 May 2023
EPS came in at $0.42 surpassing the estimated $0.23 by +82.61%, while revenue for the quarter reached $76.37m , beating expectations by +23.16%.
Earnings released on 28 Feb 2023
EPS came in at $0.25 falling short of the estimated $0.41 by -39.02%, while revenue for the quarter reached $65.80m , beating expectations by +11.81%.
Earnings released on 9 Nov 2022
EPS came in at $0.60 falling short of the estimated $2.75 by -78.18%, while revenue for the quarter reached $67.26m , beating expectations by +7.44%.
Earnings released on 27 Jul 2022
EPS came in at $0.05 falling short of the estimated $0.55 by -90.91%, while revenue for the quarter reached $108.22m , missing expectations by -49.61%.
Earnings released on 27 Apr 2022
EPS came in at $0.42 surpassing the estimated $0.40 by +5.00%, while revenue for the quarter reached $90.06m , beating expectations by +4.23%.
Earnings released on 9 Feb 2022
EPS came in at $0.55 surpassing the estimated $0.41 by +34.15%, while revenue for the quarter reached $107.68m , beating expectations by +1.23%.
Earnings released on 27 Oct 2021
EPS came in at $0.90 surpassing the estimated $0.43 by +109.30%, while revenue for the quarter reached $97.86m , beating expectations by +28.69%.
Earnings released on 28 Jul 2021
EPS came in at $0.90 surpassing the estimated $0.29 by +210.34%, while revenue for the quarter reached $100.81m , missing expectations by -9.37%.
INVA Stock Performance
Access detailed INVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
